🍽️ Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride

AI Engines For more Details: PerplexityKagi LabsYou

  1. Chemical Structure: Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride belongs to the class of isoquinoline compounds, which are aromatic heterocyclic organic compounds. Its chemical structure includes an isoquinoline core with two methoxy (CH3O) groups and a methyl (CH3) group, along with a tetrahydro (four-carbon) moiety. The hydrochloride salt form indicates that it is a salt formed by the reaction of the compound with hydrochloric acid.

  2. Pharmacological Potential: Isoquinoline derivatives have been investigated for various pharmacological activities, including anticancer, antimicrobial, anti-inflammatory, and neuroprotective properties. However, without specific information about the biological activity and mechanism of action of this particular compound, its potential health impacts on medical conditions cannot be definitively determined.

  3. Research and Development: Isoquinoline derivatives have been studied in medicinal chemistry and drug discovery programs as potential lead compounds for the development of new therapeutic agents. Researchers may investigate their structure-activity relationships, pharmacokinetics, and pharmacodynamics to identify compounds with desired biological activities and therapeutic profiles.

  4. Safety Considerations: As with any chemical compound, safety considerations are paramount, especially when considering its potential use in medical applications. Toxicity studies and risk assessments would be necessary to evaluate the safety profile of isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride, including its potential for adverse effects, cytotoxicity, genotoxicity, and other safety concerns.

  5. Regulatory Status: The regulatory status of isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride would depend on its intended use, formulation, and jurisdiction-specific regulations. Before any medical application, it would need to undergo rigorous testing and evaluation according to regulatory guidelines established by health authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bifidobacterium adolescentis Reduces

Bacteria Impacted by Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Mediterraneibacter genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study

Impact of Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 0.9 -2
ADHD 1.2 0.3 3
Age-Related Macular Degeneration and Glaucoma 0.5 0.5
Allergic Rhinitis (Hay Fever) 0.6 0.3 1
Allergies 0.7 0.9 -0.29
Allergy to milk products 0.6 0.6 0
Alopecia (Hair Loss) 0.3 0.3
Alzheimer's disease 0.9 2.4 -1.67
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.3 0.3
Ankylosing spondylitis 1.2 0.3 3
Anorexia Nervosa 0.3 0.8 -1.67
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 1.4 1.5 -0.07
Atherosclerosis 0.9 0.7 0.29
Atrial fibrillation 0.9 0.6 0.5
Autism 2.4 1.5 0.6
Autoimmune Disease 0.3 0.8 -1.67
Barrett esophagus cancer 0.3 0.3
benign prostatic hyperplasia 0.3 -0.3
Biofilm 0.3 0.3
Bipolar Disorder 0.3 0.8 -1.67
Brain Trauma 0.6 1.1 -0.83
Cancer (General) 0.3 0.2 0.5
Carcinoma 0.9 0.9 0
Celiac Disease 0.7 0.9 -0.29
Cerebral Palsy 0.9 0.8 0.13
Chronic Fatigue Syndrome 0.9 0.9 0
Chronic Kidney Disease 1.7 1.5 0.13
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0.8 -1.67
Chronic Urticaria (Hives) 0.3 0.3
Coagulation / Micro clot triggering bacteria 0.5 -0.5
Cognitive Function 1.4 0.8 0.75
Colorectal Cancer 2.4 1.4 0.71
Constipation 0.3 0.5 -0.67
Coronary artery disease 0.3 1.1 -2.67
COVID-19 1 1.7 -0.7
Crohn's Disease 1.7 1.4 0.21
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 1.2 -1.2
deep vein thrombosis 0.5 0.8 -0.6
Denture Wearers Oral Shifts 0.1 0.1
Depression 1.6 2 -0.25
Dermatomyositis 0.3 -0.3
Eczema 0.3 0.3 0
Endometriosis 0.6 0.8 -0.33
Eosinophilic Esophagitis 0.3 -0.3
Epilepsy 0.9 0.6 0.5
erectile dysfunction 0.3 0.3 0
Fibromyalgia 0.8 0.6 0.33
Functional constipation / chronic idiopathic constipation 0.7 1.9 -1.71
gallstone disease (gsd) 0.3 0.8 -1.67
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.3 0.3
Generalized anxiety disorder 0.3 1.1 -2.67
Gout 0.5 0.5
Graves' disease 1.2 1.7 -0.42
Gulf War Syndrome 0.3 -0.3
Halitosis 0.6 0.6
Hashimoto's thyroiditis 2.1 1.2 0.75
Heart Failure 0.3 0.8 -1.67
Hidradenitis Suppurativa 0.3 0.3 0
High Histamine/low DAO 0.5 0.3 0.67
hyperglycemia 0.1 0.6 -5
Hyperlipidemia (High Blood Fats) 0.6 0.3 1
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1.5 1.2 0.25
Hypothyroidism 0.3 -0.3
Hypoxia 0.6 0.3 1
IgA nephropathy (IgAN) 0.3 1.2 -3
Inflammatory Bowel Disease 1.2 1.7 -0.42
Insomnia 0.6 1.1 -0.83
Intelligence 0.3 0.3
Intracranial aneurysms 0.3 0.6 -1
Irritable Bowel Syndrome 2.4 1.7 0.41
ischemic stroke 0.9 0.8 0.13
Liver Cirrhosis 1.5 1.4 0.07
Long COVID 1.3 1.6 -0.23
Low bone mineral density 0.5 -0.5
Lung Cancer 0.1 0.1
Mast Cell Issues / mastitis 0.3 -0.3
ME/CFS with IBS 0.6 -0.6
ME/CFS without IBS 0.6 -0.6
Menopause 0 0.5 0
Metabolic Syndrome 1.7 1.5 0.13
Mood Disorders 1.7 1.8 -0.06
multiple chemical sensitivity [MCS] 0.3 0.3
Multiple Sclerosis 0.4 1.1 -1.75
Multiple system atrophy (MSA) 0.1 0.3 -2
myasthenia gravis 0.5 -0.5
neuropathic pain 0.9 -0.9
Neuropathy (all types) 0.7 -0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.1 1.2 -0.09
NonCeliac Gluten Sensitivity 0.9 0.6 0.5
Obesity 2.4 1.5 0.6
obsessive-compulsive disorder 0.6 1.2 -1
Osteoarthritis 0.3 0.6 -1
Osteoporosis 1.1 0.3 2.67
Parkinson's Disease 2.2 1.5 0.47
Polycystic ovary syndrome 1.1 1.1 0
Postural orthostatic tachycardia syndrome 0.3 -0.3
Premenstrual dysphoric disorder 0.6 0.6
primary biliary cholangitis 0.3 0.3 0
Primary sclerosing cholangitis 0.6 0.6
Psoriasis 0.7 0.8 -0.14
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.5 1.7 -0.13
Rosacea 0.9 0.8 0.13
Schizophrenia 1.3 1.4 -0.08
Sjögren syndrome 0.4 0.6 -0.5
Sleep Apnea 0.3 0.8 -1.67
Slow gastric motility / Gastroparesis 0.6 0.3 1
Small Intestinal Bacterial Overgrowth (SIBO) 0.6 0.6
Stress / posttraumatic stress disorder 1.1 1.4 -0.27
Systemic Lupus Erythematosus 0.6 0.8 -0.33
Tic Disorder 0.6 -0.6
Tourette syndrome 0.3 -0.3
Type 1 Diabetes 0.6 1.2 -1
Type 2 Diabetes 1.7 1.6 0.06
Ulcerative colitis 0.9 1.2 -0.33
Unhealthy Ageing 1.2 0.8 0.5
Vitiligo 0.6 0.3 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]